Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Director William R. Ringo sold 2,000 shares of the business’s stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $38.00, for a total value of $76,000.00. Following the sale, the director now owns 2,000 shares in the company, valued at approximately $76,000. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Shares of Five Prime Therapeutics, Inc. (FPRX) opened at 38.19 on Wednesday. The firm’s 50-day moving average price is $33.83 and its 200 day moving average price is $31.79. The firm’s market capitalization is $1.07 billion. Five Prime Therapeutics, Inc. has a 12 month low of $25.97 and a 12 month high of $60.98.

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.43). Five Prime Therapeutics had a negative net margin of 356.39% and a negative return on equity of 31.78%. The business had revenue of $7.80 million during the quarter, compared to analysts’ expectations of $8.32 million. During the same quarter last year, the company earned ($0.49) EPS. The firm’s revenue for the quarter was down 16.1% compared to the same quarter last year. Analysts anticipate that Five Prime Therapeutics, Inc. will post ($5.29) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/10/04/william-r-ringo-sells-2000-shares-of-five-prime-therapeutics-inc-fprx-stock.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. AWM Investment Company Inc. increased its stake in Five Prime Therapeutics by 25.0% in the second quarter. AWM Investment Company Inc. now owns 100,000 shares of the biotechnology company’s stock valued at $3,011,000 after purchasing an additional 20,000 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of Five Prime Therapeutics by 1.9% in the second quarter. The Manufacturers Life Insurance Company now owns 21,449 shares of the biotechnology company’s stock valued at $646,000 after buying an additional 397 shares during the last quarter. State Street Corp boosted its stake in shares of Five Prime Therapeutics by 8.4% during the second quarter. State Street Corp now owns 1,354,597 shares of the biotechnology company’s stock worth $40,782,000 after buying an additional 105,077 shares during the period. Cornerstone Capital Management Holdings LLC. boosted its stake in shares of Five Prime Therapeutics by 3.0% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 17,227 shares of the biotechnology company’s stock worth $518,000 after buying an additional 494 shares during the period. Finally, Fred Alger Management Inc. boosted its stake in shares of Five Prime Therapeutics by 25.0% during the second quarter. Fred Alger Management Inc. now owns 15,000 shares of the biotechnology company’s stock worth $452,000 after buying an additional 3,000 shares during the period. Institutional investors own 84.05% of the company’s stock.

FPRX has been the topic of a number of research reports. Jefferies Group LLC reissued a “buy” rating and issued a $55.00 price objective on shares of Five Prime Therapeutics in a report on Thursday, June 8th. BidaskClub downgraded Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd. ValuEngine raised Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Royal Bank Of Canada assumed coverage on Five Prime Therapeutics in a research report on Thursday, September 14th. They issued an “outperform” rating and a $41.00 target price on the stock. Finally, BMO Capital Markets reiterated a “hold” rating and issued a $39.00 target price on shares of Five Prime Therapeutics in a research report on Friday, September 22nd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $54.86.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Insider Buying and Selling by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Stock Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related stocks with our FREE daily email newsletter.